Literature DB >> 12450700

DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.

L López-Fuertes1, E Pérez-Jiménez, A J Vila-Coro, F Sack, S Moreno, S A Konig, C Junghans, B Wittig, M Timón, M Esteban.   

Abstract

Immunization protocols based on priming with plasmid DNA and boosting with recombinants of vaccinia virus (rVV) encoding the same antigen offer great promise for the prevention and treatment of many parasitic and viral infections for which conventional vaccination has little or no effect. To overcome some of the potential problems associated to the use of plasmids, we have developed minimalistic, immunogenically defined, gene expression (MIDGE((R))) vectors. These linear vectors contain only the minimum sequence required for gene expression and can be chemically modified to increase the immune response. Here, we demonstrate that MIDGE vectors coding for the LACK antigen confer a highly effective protection against Leishmania infection in susceptible Balb/c mice. Protection is achieved at lower doses of vector compared to conventional plasmids. This efficacy could be greatly improved by the addition of a nuclear localization signal (NLS) peptide to the end of the MIDGE vector. In fact, immunization with two doses of NLS-modified MIDGE conferred similar or even better protection than that achieved by priming with plasmid DNA followed by boosting with rVV. These results demonstrate that MIDGE vectors are a good alternative to plasmid and rVV for immunization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450700     DOI: 10.1016/s0264-410x(02)00450-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells.

Authors:  P L Mok; S K Cheong; C F Leong; K H Chua; O Ainoon
Journal:  Cytotechnology       Date:  2011-12-10       Impact factor: 2.058

Review 2.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

3.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

Review 5.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

6.  Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology.

Authors:  Michael Forgber; Rajatava Basu; Kaushik Roychoudhury; Stephan Theinert; Syamal Roy; Shyam Sundar; Peter Walden
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

7.  Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Authors:  Christiane L Schnabel; P Steinig; M Koy; H-J Schuberth; C Juhls; D Oswald; B Wittig; S Willenbrock; H Murua Escobar; C Pfarrer; B Wagner; P Jaehnig; A Moritz; K Feige; J-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-23       Impact factor: 2.741

8.  Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain.

Authors:  Halina Machelska; Matthias Schroff; Detlef Oswald; Waltraud Binder; Nicolle Sitte; Shaaban A Mousa; Heike L Rittner; Alexander Brack; Dominika Labuz; Melanie Busch; Burghardt Wittig; Michael Schäfer; Christoph Stein
Journal:  Mol Pain       Date:  2009-12-14       Impact factor: 3.395

9.  A novel micro-linear vector for in vitro and in vivo gene delivery and its application for EBV positive tumors.

Authors:  Hong-Sheng Wang; Zhuo-Jia Chen; Ge Zhang; Xue-Ling Ou; Xiang-Ling Yang; Chris K C Wong; John P Giesy; Jun Du; Shou-Yi Chen
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Construction and characterization of an in-vivo linear covalently closed DNA vector production system.

Authors:  Nafiseh Nafissi; Roderick Slavcev
Journal:  Microb Cell Fact       Date:  2012-12-06       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.